A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder

Abstract

No studies to date have evaluated SLC6A2 and SLC6A4 genetic polymorphisms influencing antidepressant response to desvenlafaxine. We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. Results revealed that homozygotes for the SLC6A4 HTTLPR S allele showed a 33% HDRS reduction compared to a 58% reduction for L allele carriers (p=0.037). No results survived adjustments for covariates or multiple comparisons. While these results need to be interpreted cautiously, they provide preliminary support for the SLC6A4 HTTLPR polymorphism as potential modifier of desvenlafaxine efficacy.

Key words

desvenlafaxine - antidepressant - pharmacogenetics - depression - SNRI

• References

• 1 Ng CH, Schweitzer I, Norman T et al. The emerging role of pharmacogenetics: implications for clinical psychiatry. Aust N Z J Psychiatry 2004; 38: 483-489
• 2 Ng CH, Norman TR, Naing KO et al. A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. Int Clin Psychopharmacol 2006; 21: 87-92
• 3 Hicks JK, Bishop JR, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
• 4 Proft F, Kopf J, Olmes D et al. SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome. Pharmacopsychiatry 2014; 47: 245-250
• 5 Laoutidis ZG, Kioulos KT. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry 2015; 48: 187-199
• 6 Hamilton M. A rating for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
• 7 Guy W edited by Rush AJ. Clinical Global Impressions Scale (CGI). Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 100-102
• 8 Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100
• 9 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4^th ed. Washington (DC): American Psychiatric Association; 2000
• 10 Ng C, Sarris J, Singh A et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol. 2013 28. 516-522
• 11 Lee SH, Choi TK, Lee E et al. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology. 2010 62. 198-206